E.Coli Infections Clinical Trial
Official title:
Evaluation of a Candidate Vaccine Against Uropathogenic Escherichia Coli in Women With a Clinical History of Recurrent Urinary Tract Infection
This Phase I multi-center placebo controlled study is conducted in healthy women with a history of recurrent urinary tract infections (UTI) aged between 18 and 70 years.
GlycoVaxyn is a Swiss company that has developed a multivalent bioconjugate vaccine for the
prevention of E.coli-infections. Cystitis is the most common UTI, however kidney infections
or bacteremia are possible. The E. coli bacterium is responsible for 85 % of all UTIs.
The objectives of this trial are to assess the safety and ability to elicit an immune
response of the candidate vaccine as well as the effectiveness of the vaccine in the
reduction in UTIs .
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04087681 -
Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1)
|
||
| Completed |
NCT05277350 -
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT03968289 -
Study to Collect Information About Serious Infections Caused by E.Coli Bacteria
|
||
| Completed |
NCT03021434 -
Trial of Low-cost Microbiological Water Test Kits
|
N/A |